Loading...
•
Dec 31, 2023
Aurinia Q4 2023 Earnings Report
Aurinia reported Q4 2023 earnings with revenue growth and strategic focus on LUPKYNIS.
Key Takeaways
Aurinia Pharmaceuticals Inc. reported a strong fourth quarter and full-year 2023, with a focus on driving commercial execution of LUPKYNIS and implementing operational changes to enhance shareholder value. The company reaffirmed its 2024 net product revenue guidance and announced a share repurchase program of up to $150 million.
Total net revenue for Q4 2023 was $45.1 million, a 59% increase compared to Q4 2022.
Net product revenue for Q4 2023 was $42.3 million, a 49% increase compared to Q4 2022.
The company had $350.7 million in cash, cash equivalents, restricted cash, and investments as of December 31, 2023.
Aurinia is discontinuing development of AUR200 and AUR300 to focus on LUPKYNIS and expects $50-55 million in annual cost savings.
Revenue by Segment
Forward Guidance
Aurinia reaffirms its 2024 net product revenue guidance of $200 - $220 million, discontinue future development of AUR200 and AUR300 research and development programs ,and expects operational cost savings of approximately $50 - $55 million annually.
Positive Outlook
- Reaffirms 2024 net product revenue guidance of $200 - $220 million
- Expected operational cost savings of approximately $50 - $55 million annually
- Focus on driving commercial execution of the LUPKYNIS business
- Initiation of a share repurchase program of up to $150 million
- The company believes that it has sufficient financial resources to fund its operations for at least the next few years
Challenges Ahead
- One-time charge in the first quarter of 2024 of approximately $11 - $15 million due to discontinuing development of AUR200 and AUR300
- Anticipates reducing employee headcount by at least 25% by the end of the first quarter of 2024
- There is no assurance the Exemptive Relief will be granted on the terms applied for or at all
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...